Amicus gets FDA approval for Pombiliti + Opfolda to treat Pompe disease
Amicus Therapeutics has received the US Food and Drug Administration (FDA) approval for its Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) 65mg capsules to treat late-onset Pompe disease (LOPD).